1
|
Abratenko P, Alterkait O, Andrade Aldana D, Anthony J, Arellano L, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barr G, Barrow J, Basque V, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhat A, Bhattacharya M, Bishai M, Blake A, Bogart B, Bolton T, Book JY, Camilleri L, Cao Y, Caratelli D, Caro Terrazas I, Cavanna F, Cerati G, Chen Y, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Del Tutto M, Dennis SR, Detje P, Devitt A, Diurba R, Djurcic Z, Dorrill R, Duffy K, Dytman S, Eberly B, Englezos P, Ereditato A, Evans JJ, Fine R, Finnerud OG, Foreman W, Fleming BT, Foppiani N, Franco D, Furmanski AP, Garcia-Gamez D, Gardiner S, Ge G, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu W, Guenette R, Guzowski P, Hagaman L, Hen O, Hicks R, Hilgenberg C, Horton-Smith GA, Imani Z, Irwin B, Itay R, James C, Ji X, Jiang L, Jo JH, Johnson RA, Jwa YJ, Kalra D, Kamp N, Karagiorgi G, Ketchum W, Kirby M, Kobilarcik T, Kreslo I, Leibovitch MB, Lepetic I, Li JY, Li K, Li Y, Lin K, Littlejohn BR, Louis WC, Luo X, Mariani C, Marsden D, Marshall J, Martinez N, Martinez Caicedo DA, Mason K, Mastbaum A, McConkey N, Meddage V, Miller K, Mills J, Mogan A, Mohayai T, Mooney M, Moor AF, Moore CD, Mora Lepin L, Mulleriababu S, Naples D, Navrer-Agasson A, Nayak N, Nebot-Guinot M, Nowak J, Oza N, Palamara O, Pallat N, Paolone V, Papadopoulou A, Papavassiliou V, Parkinson HB, Pate SF, Patel N, Pavlovic Z, Piasetzky E, Ponce-Pinto ID, Pophale I, Prince S, Qian X, Raaf JL, Radeka V, Rafique A, Reggiani-Guzzo M, Ren L, Rochester L, Rodriguez Rondon J, Rosenberg M, Ross-Lonergan M, Rudolf von Rohr C, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Shi J, Snider EL, Soderberg M, Söldner-Rembold S, Spitz J, Stancari M, John JS, Strauss T, Sword-Fehlberg S, Szelc AM, Tang W, Taniuchi N, Terao K, Thorpe C, Torbunov D, Totani D, Toups M, Tsai YT, Tyler J, Uchida MA, Usher T, Viren B, Weber M, Wei H, White AJ, Williams Z, Wolbers S, Wongjirad T, Wospakrik M, Wresilo K, Wright N, Wu W, Yandel E, Yang T, Yates LE, Yu HW, Zeller GP, Zennamo J, Zhang C. First Measurement of η Meson Production in Neutrino Interactions on Argon with MicroBooNE. PHYSICAL REVIEW LETTERS 2024; 132:151801. [PMID: 38683006 DOI: 10.1103/physrevlett.132.151801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 01/04/2024] [Accepted: 03/13/2024] [Indexed: 05/01/2024]
Abstract
We present a measurement of η production from neutrino interactions on argon with the MicroBooNE detector. The modeling of resonant neutrino interactions on argon is a critical aspect of the neutrino oscillation physics program being carried out by the DUNE and Short Baseline Neutrino programs. η production in neutrino interactions provides a powerful new probe of resonant interactions, complementary to pion channels, and is particularly suited to the study of higher-order resonances beyond the Δ(1232). We measure a flux-integrated cross section for neutrino-induced η production on argon of 3.22±0.84(stat)±0.86(syst) 10^{-41} cm^{2}/nucleon. By demonstrating the successful reconstruction of the two photons resulting from η production, this analysis enables a novel calibration technique for electromagnetic showers in GeV accelerator neutrino experiments.
Collapse
|
2
|
Abratenko P, Alterkait O, Andrade Aldana D, Arellano L, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barr G, Barrow D, Barrow J, Basque V, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhat A, Bhattacharya M, Bishai M, Blake A, Bogart B, Bolton T, Book JY, Brunetti MB, Camilleri L, Cao Y, Caratelli D, Cavanna F, Cerati G, Chappell A, Chen Y, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Cross R, Del Tutto M, Dennis SR, Detje P, Devitt A, Diurba R, Djurcic Z, Dorrill R, Duffy K, Dytman S, Eberly B, Englezos P, Ereditato A, Evans JJ, Fine R, Finnerud OG, Foreman W, Fleming BT, Franco D, Furmanski AP, Gao F, Garcia-Gamez D, Gardiner S, Ge G, Gollapinni S, Gramellini E, Green P, Greenlee H, Gu L, Gu W, Guenette R, Guzowski P, Hagaman L, Hen O, Hilgenberg C, Horton-Smith GA, Imani Z, Irwin B, Ismail M, James C, Ji X, Jo JH, Johnson RA, Jwa YJ, Kalra D, Kamp N, Karagiorgi G, Ketchum W, Kirby M, Kobilarcik T, Kreslo I, Leibovitch MB, Lepetic I, Li JY, Li K, Li Y, Lin K, Littlejohn BR, Liu H, Louis WC, Luo X, Mariani C, Marsden D, Marshall J, Martinez N, Martinez Caicedo DA, Martynenko S, Mastbaum A, Mawby I, McConkey N, Meddage V, Micallef J, Miller K, Mogan A, Mohayai T, Mooney M, Moor AF, Moore CD, Mora Lepin L, Moudgalya MM, Mulleriababu S, Naples D, Navrer-Agasson A, Nayak N, Nebot-Guinot M, Nowak J, Oza N, Palamara O, Pallat N, Paolone V, Papadopoulou A, Papavassiliou V, Parkinson HB, Pate SF, Patel N, Pavlovic Z, Piasetzky E, Pophale I, Qian X, Raaf JL, Radeka V, Rafique A, Reggiani-Guzzo M, Ren L, Rochester L, Rodriguez Rondon J, Rosenberg M, Ross-Lonergan M, Rudolf von Rohr C, Safa I, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Shi J, Snider EL, Soderberg M, Söldner-Rembold S, Spitz J, Stancari M, St John J, Strauss T, Szelc AM, Tang W, Taniuchi N, Terao K, Thorpe C, Torbunov D, Totani D, Toups M, Tsai YT, Tyler J, Uchida MA, Usher T, Viren B, Weber M, Wei H, White AJ, Wolbers S, Wongjirad T, Wospakrik M, Wresilo K, Wu W, Yandel E, Yang T, Yates LE, Yu HW, Zeller GP, Zennamo J, Zhang C. Search for Heavy Neutral Leptons in Electron-Positron and Neutral-Pion Final States with the MicroBooNE Detector. PHYSICAL REVIEW LETTERS 2024; 132:041801. [PMID: 38335355 DOI: 10.1103/physrevlett.132.041801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Accepted: 11/30/2023] [Indexed: 02/12/2024]
Abstract
We present the first search for heavy neutral leptons (HNLs) decaying into νe^{+}e^{-} or νπ^{0} final states in a liquid-argon time projection chamber using data collected with the MicroBooNE detector. The data were recorded synchronously with the NuMI neutrino beam from Fermilab's main injector corresponding to a total exposure of 7.01×10^{20} protons on target. We set upper limits at the 90% confidence level on the mixing parameter |U_{μ4}|^{2} in the mass ranges 10≤m_{HNL}≤150 MeV for the νe^{+}e^{-} channel and 150≤m_{HNL}≤245 MeV for the νπ^{0} channel, assuming |U_{e4}|^{2}=|U_{τ4}|^{2}=0. These limits represent the most stringent constraints in the mass range 35
Collapse
|
3
|
Casaro S, Pérez-Báez J, Bisinotto RS, Chebel RC, Prim JG, Gonzalez TD, Gomes GC, Tao S, Toledo IM, do Amaral BC, Bollati JM, Zenobi MG, Martinez N, Dahl GE, Santos JEP, Galvão KN. Association between prepartum body condition score and prepartum and postpartum dry matter intake and energy balance in multiparous Holstein cows. J Dairy Sci 2024:S0022-0302(24)00047-X. [PMID: 38278298 DOI: 10.3168/jds.2023-24047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 12/22/2023] [Indexed: 01/28/2024]
Abstract
The objectives of this retrospective observational study were to investigate the association between body condition score (BCS) at 21 d before calving with prepartum and postpartum dry matter intake (DMI), energy balance (EB), and milk yield. Data from 427 multigravid cows from 11 different experiments conducted at the University of Florida were used. Cows were classified according to their BCS at 21 d before calving as FAT (BCS ≥4.00; n = 83), MOD (BCS 3.25 to 3.75; n = 287), and THIN (BCS ≤3.00; n = 57). Daily DMI from -21 to -1 and from +1 to +28 DIM was individually recorded. Energy balance was calculated as the difference between net energy for lactation consumed and required. Dry matter intake in FAT cows was lesser than in MOD and THIN cows both prepartum (FAT = 9.97 ± 0.21, MOD = 11.15 ± 0.14, THIN = 11.92 ± 0.22 kg/d) and postpartum (FAT = 14.35 ± 0.49, MOD = 15.47 ± 0.38, THIN = 16.09 ± 0.47 kg/d). Dry matter intake was also lesser for MOD cows compared with THIN cows prepartum, but not postpartum. Energy balance in FAT cows was lesser than in MOD and THIN cows both prepartum (FAT = -4.16 ± 0.61, MOD = -1.20 ± 0.56, THIN = 0.88 ± 0.62 Mcal/d) and postpartum (FAT = -12.77 ± 0.50, MOD = -10.13 ± 0.29, THIN = -6.14 ± 0.51 Mcal/d). Energy balance was also lesser for MOD cows compared with THIN cows both prepartum and postpartum. There was a quadratic association between BCS at 21 d before calving and milk yield. Increasing BCS from 2.5 to 3.5 was associated with an increase in daily milk yield of 6.0 kg and 28 d cumulative milk of 147 kg. Increasing BCS from 3.5 to 4.5 was associated with a decrease in daily milk yield of 4.4 kg and 28 d cumulative milk of 116 kg. In summary, a moderated BCS at 21 d before calving was associated with intermediate DMI and EB pre- and postpartum but greater milk yield compared with thinner and fatter cows. Our findings indicate that a moderated BCS is ideal for ensuring a successful lactation.
Collapse
|
4
|
Abratenko P, Alterkait O, Andrade Aldana D, Anthony J, Arellano L, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barr G, Barrow J, Basque V, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhattacharya M, Bishai M, Blake A, Bogart B, Bolton T, Book JY, Camilleri L, Caratelli D, Caro Terrazas I, Cavanna F, Cerati G, Chen Y, Cohen EO, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Del Tutto M, Dennis SR, Detje P, Devitt A, Diurba R, Djurcic Z, Dorrill R, Duffy K, Dytman S, Eberly B, Ereditato A, Evans JJ, Fine R, Finnerud OG, Foreman W, Fleming BT, Foppiani N, Franco D, Furmanski AP, Garcia-Gamez D, Gardiner S, Ge G, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu W, Guenette R, Guzowski P, Hagaman L, Hen O, Hicks R, Hilgenberg C, Horton-Smith GA, Irwin B, Itay R, James C, Ji X, Jiang L, Jo JH, Johnson RA, Jwa YJ, Kalra D, Kamp N, Karagiorgi G, Ketchum W, Kirby M, Kobilarcik T, Kreslo I, Leibovitch MB, Lepetic I, Li JY, Li K, Li Y, Lin K, Littlejohn BR, Louis WC, Luo X, Mariani C, Marsden D, Marshall J, Martinez N, Martinez Caicedo DA, Mason K, Mastbaum A, McConkey N, Meddage V, Miller K, Mills J, Mogan A, Mohayai T, Mooney M, Moor AF, Moore CD, Mora Lepin L, Mousseau J, Mulleriababu S, Naples D, Navrer-Agasson A, Nayak N, Nebot-Guinot M, Nowak J, Oza N, Palamara O, Pallat N, Paolone V, Papadopoulou A, Papavassiliou V, Parkinson HB, Pate SF, Patel N, Pavlovic Z, Piasetzky E, Ponce-Pinto ID, Pophale I, Prince S, Qian X, Raaf JL, Radeka V, Rafique A, Reggiani-Guzzo M, Ren L, Rochester L, Rodriguez Rondon J, Rosenberg M, Ross-Lonergan M, Rudolf von Rohr C, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Shi J, Snider EL, Soderberg M, Söldner-Rembold S, Spitz J, Stancari M, John JS, Strauss T, Sword-Fehlberg S, Szelc AM, Tang W, Taniuchi N, Terao K, Thorpe C, Torbunov D, Totani D, Toups M, Tsai YT, Tyler J, Uchida MA, Usher T, Viren B, Weber M, Wei H, White AJ, Williams Z, Wolbers S, Wongjirad T, Wospakrik M, Wresilo K, Wright N, Wu W, Yandel E, Yang T, Yates LE, Yu HW, Zeller GP, Zennamo J, Zhang C. First Double-Differential Measurement of Kinematic Imbalance in Neutrino Interactions with the MicroBooNE Detector. PHYSICAL REVIEW LETTERS 2023; 131:101802. [PMID: 37739352 DOI: 10.1103/physrevlett.131.101802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 05/09/2023] [Accepted: 07/14/2023] [Indexed: 09/24/2023]
Abstract
We report the first measurement of flux-integrated double-differential quasielasticlike neutrino-argon cross sections, which have been made using the Booster Neutrino Beam and the MicroBooNE detector at Fermi National Accelerator Laboratory. The data are presented as a function of kinematic imbalance variables which are sensitive to nuclear ground-state distributions and hadronic reinteraction processes. We find that the measured cross sections in different phase-space regions are sensitive to different nuclear effects. Therefore, they enable the impact of specific nuclear effects on the neutrino-nucleus interaction to be isolated more completely than was possible using previous single-differential cross section measurements. Our results provide precision data to help test and improve neutrino-nucleus interaction models. They further support ongoing neutrino-oscillation studies by establishing phase-space regions where precise reaction modeling has already been achieved.
Collapse
|
5
|
Abratenko P, Andrade Aldana D, Anthony J, Arellano L, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barr G, Barrow J, Basque V, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhattacharya M, Bishai M, Blake A, Bogart B, Bolton T, Book JY, Camilleri L, Caratelli D, Caro Terrazas I, Cavanna F, Cerati G, Chen Y, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Del Tutto M, Dennis SR, Detje P, Devitt A, Diurba R, Djurcic Z, Dorrill R, Duffy K, Dytman S, Eberly B, Ereditato A, Evans JJ, Fine R, Finnerud OG, Foreman W, Fleming BT, Foppiani N, Franco D, Furmanski AP, Garcia-Gamez D, Gardiner S, Ge G, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu W, Guenette R, Guzowski P, Hagaman L, Hen O, Hicks R, Hilgenberg C, Horton-Smith GA, Irwin B, Itay R, James C, Ji X, Jiang L, Jo JH, Johnson RA, Jwa YJ, Kalra D, Kamp N, Karagiorgi G, Ketchum W, Kirby M, Kobilarcik T, Kreslo I, Leibovitch MB, Lepetic I, Li JY, Li K, Li Y, Lin K, Littlejohn BR, Louis WC, Luo X, Mariani C, Marsden D, Marshall J, Martinez N, Martinez Caicedo DA, Mason K, Mastbaum A, McConkey N, Meddage V, Miller K, Mills J, Mogan A, Mohayai T, Mooney M, Moor AF, Moore CD, Mora Lepin L, Mousseau J, Mulleriababu S, Naples D, Navrer-Agasson A, Nayak N, Nebot-Guinot M, Nowak J, Nunes M, Oza N, Palamara O, Pallat N, Paolone V, Papadopoulou A, Papavassiliou V, Parkinson HB, Pate SF, Patel N, Pavlovic Z, Piasetzky E, Ponce-Pinto ID, Pophale I, Prince S, Qian X, Raaf JL, Radeka V, Rafique A, Reggiani-Guzzo M, Ren L, Rochester L, Rodriguez Rondon J, Rosenberg M, Ross-Lonergan M, Rudolf von Rohr C, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Shi J, Snider EL, Soderberg M, Söldner-Rembold S, Spitz J, Stancari M, John JS, Strauss T, Sword-Fehlberg S, Szelc AM, Tang W, Taniuchi N, Terao K, Thorpe C, Torbunov D, Totani D, Toups M, Tsai YT, Tyler J, Uchida MA, Usher T, Viren B, Weber M, Wei H, White AJ, Williams Z, Wolbers S, Wongjirad T, Wospakrik M, Wresilo K, Wright N, Wu W, Yandel E, Yang T, Yates LE, Yu HW, Zeller GP, Zennamo J, Zhang C. First Measurement of Quasielastic Λ Baryon Production in Muon Antineutrino Interactions in the MicroBooNE Detector. PHYSICAL REVIEW LETTERS 2023; 130:231802. [PMID: 37354393 DOI: 10.1103/physrevlett.130.231802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 04/07/2023] [Accepted: 04/28/2023] [Indexed: 06/26/2023]
Abstract
We present the first measurement of the cross section of Cabibbo-suppressed Λ baryon production, using data collected with the MicroBooNE detector when exposed to the neutrinos from the main injector beam at the Fermi National Accelerator Laboratory. The data analyzed correspond to 2.2×10^{20} protons on target running in neutrino mode, and 4.9×10^{20} protons on target running in anti-neutrino mode. An automated selection is combined with hand scanning, with the former identifying five candidate Λ production events when the signal was unblinded, consistent with the GENIE prediction of 5.3±1.1 events. Several scanners were employed, selecting between three and five events, compared with a prediction from a blinded Monte Carlo simulation study of 3.7±1.0 events. Restricting the phase space to only include Λ baryons that decay above MicroBooNE's detection thresholds, we obtain a flux averaged cross section of 2.0_{-1.7}^{+2.2}×10^{-40} cm^{2}/Ar, where statistical and systematic uncertainties are combined.
Collapse
|
6
|
Abratenko P, Andrade Aldana D, Anthony J, Arellano L, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barr G, Barrow J, Basque V, Bathe-Peters L, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhattacharya M, Bishai M, Blake A, Bogart B, Bolton T, Book JY, Camilleri L, Caratelli D, Caro Terrazas I, Cavanna F, Cerati G, Chen Y, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Del Tutto M, Dennis SR, Detje P, Devitt A, Diurba R, Dorrill R, Duffy K, Dytman S, Eberly B, Ereditato A, Evans JJ, Fine R, Finnerud OG, Foreman W, Fleming BT, Foppiani N, Franco D, Furmanski AP, Garcia-Gamez D, Gardiner S, Ge G, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu W, Guenette R, Guzowski P, Hagaman L, Hen O, Hicks R, Hilgenberg C, Horton-Smith GA, Irwin B, Itay R, James C, Ji X, Jiang L, Jo JH, Johnson RA, Jwa YJ, Kalra D, Kamp N, Karagiorgi G, Ketchum W, Kirby M, Kobilarcik T, Kreslo I, Leibovitch MB, Lepetic I, Li JY, Li K, Li Y, Lin K, Littlejohn BR, Louis WC, Luo X, Manivannan K, Mariani C, Marsden D, Marshall J, Martinez N, Martinez Caicedo DA, Mason K, Mastbaum A, McConkey N, Meddage V, Miller K, Mills J, Mogan A, Mohayai T, Mooney M, Moor AF, Moore CD, Mora Lepin L, Mousseau J, Mulleriababu S, Naples D, Navrer-Agasson A, Nayak N, Nebot-Guinot M, Nowak J, Nunes M, Oza N, Palamara O, Pallat N, Paolone V, Papadopoulou A, Papavassiliou V, Parkinson HB, Pate SF, Patel N, Pavlovic Z, Piasetzky E, Ponce-Pinto ID, Pophale I, Prince S, Qian X, Raaf JL, Radeka V, Reggiani-Guzzo M, Ren L, Rochester L, Rodriguez Rondon J, Rosenberg M, Ross-Lonergan M, Rudolf von Rohr C, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Shi J, Smith A, Snider EL, Soderberg M, Söldner-Rembold S, Spitz J, Stancari M, St John J, Strauss T, Sword-Fehlberg S, Szelc AM, Tang W, Taniuchi N, Terao K, Thorpe C, Torbunov D, Totani D, Toups M, Tsai YT, Tyler J, Uchida MA, Usher T, Viren B, Weber M, Wei H, White AJ, Williams Z, Wolbers S, Wongjirad T, Wospakrik M, Wresilo K, Wright N, Wu W, Yandel E, Yang T, Yates LE, Yu HW, Zeller GP, Zennamo J, Zhang C. First Constraints on Light Sterile Neutrino Oscillations from Combined Appearance and Disappearance Searches with the MicroBooNE Detector. PHYSICAL REVIEW LETTERS 2023; 130:011801. [PMID: 36669216 DOI: 10.1103/physrevlett.130.011801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Accepted: 12/08/2022] [Indexed: 06/17/2023]
Abstract
We present a search for eV-scale sterile neutrino oscillations in the MicroBooNE liquid argon detector, simultaneously considering all possible appearance and disappearance effects within the 3+1 active-to-sterile neutrino oscillation framework. We analyze the neutrino candidate events for the recent measurements of charged-current ν_{e} and ν_{μ} interactions in the MicroBooNE detector, using data corresponding to an exposure of 6.37×10^{20} protons on target from the Fermilab booster neutrino beam. We observe no evidence of light sterile neutrino oscillations and derive exclusion contours at the 95% confidence level in the plane of the mass-squared splitting Δm_{41}^{2} and the sterile neutrino mixing angles θ_{μe} and θ_{ee}, excluding part of the parameter space allowed by experimental anomalies. Cancellation of ν_{e} appearance and ν_{e} disappearance effects due to the full 3+1 treatment of the analysis leads to a degeneracy when determining the oscillation parameters, which is discussed in this Letter and will be addressed by future analyses.
Collapse
|
7
|
Castellanos-Ortega Á, Broch MJ, Palacios-Castañeda D, Gómez-Tello V, Valdivia M, Vicent C, Madrid I, Martinez N, Párraga MJ, Sancho E, Fuentes-Dura MDC, Sancerni-Beitia MD, García-Ros R. Competency assessment of residents of Intensive Care Medicine through a simulation-based objective structured clinical evaluation (OSCE). A multicenter observational study. Med Intensiva 2022; 46:491-500. [PMID: 36057440 DOI: 10.1016/j.medine.2022.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 01/22/2022] [Indexed: 06/15/2023]
Abstract
OBJECTIVES The current official model of training in Intensive Care Medicine (ICM) in Spain is based on exposure to experiences through clinical rotations. The main objective was to determine the level of competency (I novice to V independent practitioner) achieved by the residents at the end of the 3rd year of training (R3) in ICM through a simulation-based OSCE. Secondary objectives were: (1) To identify gaps in performance, and (2) To investigate the reliability and feasibility of conducting simulation-based assessment at multiple sites. DESIGN Observational multicenter study. SETTING Thirteen Spanish ICU Departments. PARTICIPANTS Thirty six R3. INTERVENTION The participants performed on five, 15-min, high-fidelity crisis scenarios in four simulation centers. The performances were video recorded for later scoring by trained raters. MAIN VARIABLES OF INTEREST Via a Delphi technique, an independent panel of expert intensivists identified critical essential performance elements (CEPE) for each scenario to define the levels of competency. RESULTS A total of 176 performances were analyzed. The internal consistency of the check-lists were adequate (KR-20 range 0.64-0.79). Inter-rater reliability was strong [median Intraclass Correlation Coefficient across scenarios: 0.89 (0.65-0.97)]. Competency levels achieved by R3 were: Level I (18.8%), II (35.2%), III (42.6%), IV/V (3.4%). Overall, a great heterogeneity in performance was observed. CONCLUSION The expected level of competency after one year in the ICU was achieved only in half of the performances. A more evidence-based educational approach is needed. Multiple center simulation-based assessment showed feasibility and reliability as an evaluation method of competency. TRIAL REGISTRATION COBALIDATION. NCT04278976. (https://register. CLINICALTRIALS gov).
Collapse
|
8
|
Abud AA, Abi B, Acciarri R, Acero MA, Adames MR, Adamov G, Adamowski M, Adams D, Adinolfi M, Aduszkiewicz A, Aguilar J, Ahmad Z, Ahmed J, Aimard B, Ali-Mohammadzadeh B, Alion T, Allison K, Monsalve SA, AlRashed M, Alt C, Alton A, Alvarez R, Amedo P, Anderson J, Andreopoulos C, Andreotti M, Andrews M, Andrianala F, Andringa S, Anfimov N, Ankowski A, Antoniassi M, Antonova M, Antoshkin A, Antusch S, Aranda-Fernandez A, Arellano L, Arnold LO, Arroyave MA, Asaadi J, Asquith L, Aurisano A, Aushev V, Autiero D, Lara VA, Ayala-Torres M, Azfar F, Back A, Back H, Back JJ, Backhouse C, Bagaturia I, Bagby L, Balashov N, Balasubramanian S, Baldi P, Baller B, Bambah B, Barao F, Barenboim G, Alzas PB, Barker G, Barkhouse W, Barnes C, Barr G, Monarca JB, Barros A, Barros N, Barrow JL, Basharina-Freshville A, Bashyal A, Basque V, Batchelor C, Chagas EBD, Battat JBR, Battisti F, Bay F, Bazetto MCQ, Alba JLLB, Beacom JF, Bechetoille E, Behera B, Beigbeder C, Bellantoni L, Bellettini G, Bellini V, Beltramello O, Benekos N, Montiel CB, Neves FB, Berger J, Berkman S, Bernardini P, Berner RM, Bersani A, Bertolucci S, Betancourt M, Rodríguez AB, Bevan A, Bezawada Y, Bezerra TJC, Bhardwaj A, Bhatnagar V, Bhattacharjee M, Bhattarai D, Bhuller S, Bhuyan B, Biagi S, Bian J, Biassoni M, Biery K, Bilki B, Bishai M, Bitadze A, Blake A, Blaszczyk F, Blazey GC, Blucher E, Boissevain J, Bolognesi S, Bolton T, Bomben L, Bonesini M, Bongrand M, Bonilla-Diaz C, Bonini F, Booth A, Boran F, Bordoni S, Borkum A, Bostan N, Bour P, Bourgeois C, Boyden D, Bracinik J, Braga D, Brailsford D, Branca A, Brandt A, Bremer J, Breton D, Brew C, Brice SJ, Brizzolari C, Bromberg C, Brooke J, Bross A, Brunetti G, Brunetti M, Buchanan N, Budd H, Butorov I, Cagnoli I, Cai T, Caiulo D, Calabrese R, Calafiura P, Calcutt J, Calin M, Calvez S, Calvo E, Caminata A, Campanelli M, Caratelli D, Carber D, Carceller JC, Carini G, Carlus B, Carneiro MF, Carniti P, Terrazas IC, Carranza H, Carroll T, Forero JFC, Castillo A, Castromonte C, Catano-Mur E, Cattadori C, Cavalier F, Cavallaro G, Cavanna F, Centro S, Cerati G, Cervelli A, Villanueva AC, Chalifour M, Chappell A, Chardonnet E, Charitonidis N, Chatterjee A, Chattopadhyay S, Neyra MSSC, Chen H, Chen M, Chen Y, Chen Z, Chen-Wishart Z, Cheon Y, Cherdack D, Chi C, Childress S, Chirco R, Chiriacescu A, Chisnall G, Cho K, Choate S, Chokheli D, Chong PS, Christensen A, Christian D, Christodoulou G, Chukanov A, Chung M, Church E, Cicero V, Clarke P, Cline G, Coan TE, Cocco AG, Coelho JAB, Colton N, Conley E, Conley R, Conrad J, Convery M, Copello S, Cova P, Cremaldi L, Cremonesi L, Crespo-Anadón JI, Crisler M, Cristaldo E, Crnkovic J, Cross R, Cudd A, Cuesta C, Cui Y, Cussans D, Dalager O, da Motta H, Da Silva Peres L, David C, David Q, Davies GS, Davini S, Dawson J, De K, De S, Debbins P, De Bonis I, Decowski MP, De Gouvêa A, De Holanda PC, De Icaza Astiz IL, Deisting A, De Jong P, Delbart A, Delepine D, Delgado M, Dell’Acqua A, Delmonte N, De Lurgio P, de Mello Neto JRT, DeMuth DM, Dennis S, Densham C, Deptuch GW, De Roeck A, De Romeri V, De Souza G, Devi R, Dharmapalan R, Dias M, Diaz F, Díaz JS, Domizio SD, Giulio LD, Ding P, Noto LD, Dirkx G, Distefano C, Diurba R, Diwan M, Djurcic Z, Doering D, Dolan S, Dolek F, Dolinski M, Domine L, Donon Y, Douglas D, Douillet D, Dragone A, Drake G, Drielsma F, Duarte L, Duchesneau D, Duffy K, Dunne P, Dutta B, Duyang H, Dvornikov O, Dwyer D, Dyshkant A, Eads M, Earle A, Edmunds D, Eisch J, Emberger L, Emery S, Englezos P, Ereditato A, Erjavec T, Escobar C, Eurin G, Evans JJ, Ewart E, Ezeribe AC, Fahey K, Falcone A, Fani’ M, Farnese C, Farzan Y, Fedoseev D, Felix J, Feng Y, Fernandez-Martinez E, Menendez PF, Morales MF, Ferraro F, Fields L, Filip P, Filthaut F, Fiorini M, Fischer V, Fitzpatrick RS, Flanagan W, Fleming B, Flight R, Fogarty S, Foreman W, Fowler J, Fox W, Franc J, Francis K, Franco D, Freeman J, Freestone J, Fried J, Friedland A, Robayo FF, Fuess S, Furic IK, Furman K, Furmanski AP, Gabrielli A, Gago A, Gallagher H, Gallas A, Gallego-Ros A, Gallice N, Galymov V, Gamberini E, Gamble T, Ganacim F, Gandhi R, Gandrajula R, Gao F, Gao S, Garcia-Gamez D, García-Peris MÁ, Gardiner S, Gastler D, Gauvreau J, Ge G, Geffroy N, Gelli B, Gendotti A, Gent S, Ghorbani-Moghaddam Z, Giammaria P, Giammaria T, Giangiacomi N, Gibin D, Gil-Botella I, Gilligan S, Girerd C, Giri AK, Gnani D, Gogota O, Gold M, Gollapinni S, Gollwitzer K, Gomes RA, Bermeo LVG, Fajardo LSG, Gonnella F, Gonzalez-Diaz D, Gonzalez-Lopez M, Goodman MC, Goodwin O, Goswami S, Gotti C, Goudzovski E, Grace C, Gran R, Granados E, Granger P, Grant A, Grant C, Gratieri D, Green P, Greenler L, Greer J, Grenard J, Griffith WC, Groh M, Grudzinski J, Grzelak K, Gu W, Guardincerri E, Guarino V, Guarise M, Guenette R, Guerard E, Guerzoni M, Guffanti D, Guglielmi A, Guo B, Gupta A, Gupta V, Guthikonda KK, Gutierrez R, Guzowski P, Guzzo MM, Gwon S, Ha C, Haaf K, Habig A, Hadavand H, Haenni R, Hahn A, Haiston J, Hamacher-Baumann P, Hamernik T, Hamilton P, Han J, Harris DA, Hartnell J, Hartnett T, Harton J, Hasegawa T, Hasnip C, Hatcher R, Hatfield KW, Hatzikoutelis A, Hayes C, Hayrapetyan K, Hays J, Hazen E, He M, Heavey A, Heeger KM, Heise J, Henry S, Morquecho MAH, Herner K, Hewes J, Hilgenberg C, Hill T, Hillier SJ, Himmel A, Hinkle E, Hirsch LR, Ho J, Hoff J, Holin A, Hoppe E, Horton-Smith GA, Hostert M, Hourlier A, Howard B, Howell R, Hoyos J, Hristova I, Hronek MS, Huang J, Hulcher Z, Iles G, Ilic N, Iliescu AM, Illingworth R, Ingratta G, Ioannisian A, Irwin B, Isenhower L, Itay R, Jackson CM, Jain V, James E, Jang W, Jargowsky B, Jediny F, Jena D, Jeong YS, Jesús-Valls C, Ji X, Jiang L, Jiménez S, Jipa A, Johnson R, Johnson W, Johnston N, Jones B, Jones S, Judah M, Jung CK, Junk T, Jwa Y, Kabirnezhad M, Kaboth A, Kadenko I, Kakorin I, Kalitkina A, Kalra D, Kamiya F, Kaneshige N, Kaplan DM, Karagiorgi G, Karaman G, Karcher A, Karolak M, Karyotakis Y, Kasai S, Kasetti SP, Kashur L, Kazaryan N, Kearns E, Keener P, Kelly KJ, Kemp E, Kemularia O, Ketchum W, Kettell SH, Khabibullin M, Khotjantsev A, Khvedelidze A, Kim D, King B, Kirby B, Kirby M, Klein J, Klustova A, Kobilarcik T, Koehler K, Koerner LW, Koh DH, Kohn S, Koller PP, Kolupaeva L, Korablev D, Kordosky M, Kosc T, Kose U, Kostelecký VA, Kothekar K, Kralik R, Kreczko L, Krennrich F, Kreslo I, Kropp W, Kroupova T, Kubota S, Kudenko Y, Kudryavtsev VA, Kulagin S, Kumar J, Kumar P, Kunze P, Kurita N, Kuruppu C, Kus V, Kutter T, Kvasnicka J, Kwak D, Lambert A, Land B, Lane CE, Lang K, Langford T, Langstaff M, Larkin J, Lasorak P, Last D, Laundrie A, Laurenti G, Lawrence A, Lazanu I, LaZur R, Lazzaroni M, Le T, Leardini S, Learned J, LeBrun P, LeCompte T, Lee C, Lee SY, Miotto GL, Lehnert R, de Oliveira MAL, Leitner M, Lepin LM, Li SW, Li Y, Liao H, Lin CS, Lin Q, Lin S, Lineros RA, Ling J, Lister A, Littlejohn BR, Liu J, Liu Y, Lockwitz S, Loew T, Lokajicek M, Lomidze I, Long K, Lord T, LoSecco JM, Louis WC, Lu XG, Luk KB, Lunday B, Luo X, Luppi E, Lux T, Luzio VP, Maalmi J, MacFarlane D, Machado AA, Machado P, Macias CT, Macier JR, Maddalena A, Madera A, Madigan P, Magill S, Mahn K, Maio A, Major A, Maloney JA, Mandrioli G, Mandujano RC, Maneira J, Manenti L, Manly S, Mann A, Manolopoulos K, Plata MM, Manyam VN, Manzanillas L, Marchan M, Marchionni A, Marciano W, Marfatia D, Mariani C, Maricic J, Marie R, Marinho F, Marino AD, Marsden D, Marshak M, Marshall C, Marshall J, Marteau J, Martín-Albo J, Martinez N, Caicedo DAM, Miravé PM, Martynenko S, Mascagna V, Mason K, Mastbaum A, Matichard F, Matsuno S, Matthews J, Mauger C, Mauri N, Mavrokoridis K, Mawby I, Mazza R, Mazzacane A, Mazzucato E, McAskill T, McCluskey E, McConkey N, McFarland KS, McGrew C, McNab A, Mefodiev A, Mehta P, Melas P, Mena O, Mendez H, Mendez P, Méndez DP, Menegolli A, Meng G, Messier MD, Metcalf W, Mettler T, Mewes M, Meyer H, Miao T, Michna G, Miedema T, Mikola V, Milincic R, Miller G, Miller W, Mills J, Mineev O, Minotti A, Miranda OG, Miryala S, Mishra CS, Mishra SR, Mislivec A, Mitchell M, Mladenov D, Mocioiu I, Moffat K, Moggi N, Mohanta R, Mohayai TA, Mokhov N, Molina J, Bueno LM, Montagna E, Montanari A, Montanari C, Montanari D, Zetina LMM, Moon SH, Mooney M, Moor AF, Moreno D, Moretti D, Morris C, Mossey C, Mote M, Motuk E, Moura CA, Mousseau J, Mouster G, Mu W, Mualem L, Mueller J, Muether M, Mufson S, Muheim F, Muir A, Mulhearn M, Munford D, Muramatsu H, Murphy S, Musser J, Nachtman J, Nagu S, Nalbandyan M, Nandakumar R, Naples D, Narita S, Nath A, Navrer-Agasson A, Nayak N, Nebot-Guinot M, Negishi K, Nelson JK, Nesbit J, Nessi M, Newbold D, Newcomer M, Newton H, Nichol R, Nicolas-Arnaldos F, Nikolica A, Niner E, Nishimura K, Norman A, Norrick A, Northrop R, Novella P, Nowak JA, Oberling M, Ochoa-Ricoux J, Olivier A, Olshevskiy A, Onel Y, Onishchuk Y, Ott J, Pagani L, Palacio G, Palamara O, Palestini S, Paley JM, Pallavicini M, Palomares C, Vazquez WP, Pantic E, Paolone V, Papadimitriou V, Papaleo R, Papanestis A, Paramesvaran S, Parke S, Parozzi E, Parsa Z, Parvu M, Pascoli S, Pasqualini L, Pasternak J, Pater J, Patrick C, Patrizii L, Patterson RB, Patton SJ, Patzak T, Paudel A, Paulos B, Paulucci L, Pavlovic Z, Pawloski G, Payne D, Pec V, Peeters SJM, Perez AP, Pennacchio E, Penzo A, Peres OLG, Perry J, Pershey D, Pessina G, Petrillo G, Petta C, Petti R, Pia V, Piastra F, Pickering L, Pietropaolo F, Pimentel VL, Pinaroli G, Plows K, Plunkett R, Poling R, Pompa F, Pons X, Poonthottathil N, Poppi F, Pordes S, Porter J, Potekhin M, Potenza R, Potukuchi BVKS, Pozimski J, Pozzato M, Prakash S, Prakash T, Prest M, Prince S, Psihas F, Pugnere D, Qian X, Raaf JL, Radeka V, Rademacker J, Radics B, Rafique A, Raguzin E, Rai M, Rajaoalisoa M, Rakhno I, Rakotonandrasana A, Rakotondravohitra L, Rameika R, Delgado MAR, Ramson B, Rappoldi A, Raselli G, Ratoff P, Raut S, Razakamiandra RF, Rea EM, Real JS, Rebel B, Rechenmacher R, Reggiani-Guzzo M, Reichenbacher J, Reitzner SD, Sfar HR, Renshaw A, Rescia S, Resnati F, Ribas M, Riboldi S, Riccio C, Riccobene G, Rice LCJ, Ricol JS, Rigamonti A, Rigaut Y, Rincón EV, Ritchie-Yates H, Rivera D, Robert A, Rochester L, Roda M, Rodrigues P, Alonso MJR, Bonilla ER, Rondon JR, Rosauro-Alcaraz S, Rosenberg M, Rosier P, Roskovec B, Rossella M, Rossi M, Rout J, Roy P, Rubbia A, Rubbia C, Russell B, Ruterbories D, Rybnikov A, Saa-Hernandez A, Saakyan R, Sacerdoti S, Safford T, Sahu N, Sakashita K, Sala P, Samios N, Samoylov O, Sanchez MC, Sandberg V, Sanders DA, Sankey D, Santana S, Santos-Maldonado M, Saoulidou N, Sapienza P, Sarasty C, Sarcevic I, Savage G, Savinov V, Scaramelli A, Scarff A, Scarpelli A, Schefke T, Schellman H, Schifano S, Schlabach P, Schmitz D, Schneider AW, Scholberg K, Schukraft A, Segreto E, Selyunin A, Senise CR, Sensenig J, Sergi A, Sgalaberna D, Shaevitz MH, Shafaq S, Shaker F, Shamma M, Sharankova R, Sharma HR, Sharma R, Sharma RK, Shaw T, Shchablo K, Shepherd-Themistocleous C, Sheshukov A, Shin S, Shoemaker I, Shooltz D, Shrock R, Siegel H, Simard L, Sinclair J, Sinev G, Singh J, Singh J, Singh L, Singh P, Singh V, Sipos R, Sippach FW, Sirri G, Sitraka A, Siyeon K, Skarpaas K, Smith A, Smith E, Smith P, Smolik J, Smy M, Snider E, Snopok P, Snowden-Ifft D, Nunes MS, Sobel H, Soderberg M, Sokolov S, Salinas CJS, Söldner-Rembold S, Soleti SR, Solomey N, Solovov V, Sondheim WE, Sorel M, Sotnikov A, Soto-Oton J, Ugaldi FAS, Sousa A, Soustruznik K, Spagliardi F, Spanu M, Spitz J, Spooner NJC, Spurgeon K, Stancari M, Stanco L, Stanford C, Stein R, Steiner HM, Lisbôa AFS, Stewart J, Stillwell B, Stock J, Stocker F, Stokes T, Strait M, Strauss T, Strigari L, Stuart A, Suarez JG, Sunción JMS, Sullivan H, Summers D, Surdo A, Susic V, Suter L, Sutera CM, Svoboda R, Szczerbinska B, Szelc AM, Tanaka H, Tang S, Tapia A, Oregui BT, Tapper A, Tariq S, Tarpara E, Tata N, Tatar E, Tayloe R, Teklu AM, Tennessen P, Tenti M, Terao K, Ternes CA, Terranova F, Testera G, Thakore T, Thea A, Thompson JL, Thorn C, Timm SC, Tishchenko V, Tomassetti L, Tonazzo A, Torbunov D, Torti M, Tortola M, Tortorici F, Tosi N, Totani D, Toups M, Touramanis C, Travaglini R, Trevor J, Trilov S, Trzaska WH, Tsai Y, Tsai YT, Tsamalaidze Z, Tsang KV, Tsverava N, Tufanli S, Tull C, Tyley E, Tzanov M, Uboldi L, Uchida MA, Urheim J, Usher T, Uzunyan S, Vagins MR, Vahle P, Valder S, Valdiviesso GDA, Valencia E, Valentim R, Vallari Z, Vallazza E, Valle JWF, Vallecorsa S, Berg RV, de Water RGV, Forero DV, Vannerom D, Varanini F, Oliva DV, Varner G, Vasel J, Vasina S, Vasseur G, Vaughan N, Vaziri K, Ventura S, Verdugo A, Vergani S, Vermeulen MA, Verzocchi M, Vicenzi M, de Souza HV, Vignoli C, Vilela C, Viren B, Vrba T, Wachala T, Waldron AV, Wallbank M, Wallis C, Wang H, Wang J, Wang L, Wang MHLS, Wang X, Wang Y, Wang Y, Warburton K, Warner D, Wascko MO, Waters D, Watson A, Wawrowska K, Weatherly P, Weber A, Weber M, Wei H, Weinstein A, Wenman D, Wetstein M, White A, Whitehead LH, Whittington D, Wilking MJ, Wilkinson A, Wilkinson C, Williams Z, Wilson F, Wilson RJ, Wisniewski W, Wolcott J, Wongjirad T, Wood A, Wood K, Worcester E, Worcester M, Wresilo K, Wret C, Wu W, Wu W, Xiao Y, Xie F, Yaeggy B, Yandel E, Yang G, Yang K, Yang T, Yankelevich A, Yershov N, Yonehara K, Yoon YS, Young T, Yu B, Yu H, Yu H, Yu J, Yu Y, Yuan W, Zaki R, Zalesak J, Zambelli L, Zamorano B, Zani A, Zazueta L, Zeller GP, Zennamo J, Zeug K, Zhang C, Zhang S, Zhang Y, Zhao M, Zhivun E, Zhu G, Zimmerman ED, Zucchelli S, Zuklin J, Zutshi V, Zwaska R. Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC. THE EUROPEAN PHYSICAL JOURNAL. C, PARTICLES AND FIELDS 2022; 82:618. [PMID: 35859696 PMCID: PMC9288420 DOI: 10.1140/epjc/s10052-022-10549-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Accepted: 06/24/2022] [Indexed: 06/15/2023]
Abstract
DUNE is a dual-site experiment for long-baseline neutrino oscillation studies, neutrino astrophysics and nucleon decay searches. ProtoDUNE Dual Phase (DP) is a 6 × 6 × 6 m 3 liquid argon time-projection-chamber (LArTPC) that recorded cosmic-muon data at the CERN Neutrino Platform in 2019-2020 as a prototype of the DUNE Far Detector. Charged particles propagating through the LArTPC produce ionization and scintillation light. The scintillation light signal in these detectors can provide the trigger for non-beam events. In addition, it adds precise timing capabilities and improves the calorimetry measurements. In ProtoDUNE-DP, scintillation and electroluminescence light produced by cosmic muons in the LArTPC is collected by photomultiplier tubes placed up to 7 m away from the ionizing track. In this paper, the ProtoDUNE-DP photon detection system performance is evaluated with a particular focus on the different wavelength shifters, such as PEN and TPB, and the use of Xe-doped LAr, considering its future use in giant LArTPCs. The scintillation light production and propagation processes are analyzed and a comparison of simulation to data is performed, improving understanding of the liquid argon properties.
Collapse
|
9
|
Pascual T, Bermejo De Las Heras B, Martinez N, Oliveira M, Pernas Simon S, Lopez Lopez R, Ruiz Cabrero I, Alarcon J, Martinez De Dueñas E, Malon Gimenez D, Gonzalez Cao M, Manso Sanchez L, Morales Murillo S, Lopez de Ceballos H, Cortés J, Llombart Cussac A, Prat A. 95P PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
10
|
Castellanos-Ortega Á, Broch M, Palacios-Castañeda D, Gómez-Tello V, Valdivia M, Vicent C, Madrid I, Martinez N, Párraga M, Sancho E, Fuentes-Dura M, Sancerni-Beitia M, García-Ros R. Competency assessment of residents of Intensive Care Medicine through a simulation-based objective structured clinical evaluation (OSCE). A multicenter observational study. Med Intensiva 2022. [DOI: 10.1016/j.medin.2022.01.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Ali A, Niazi M, Bar-Ad V, Werner-Wasik M, Andrews D, Farrell C, Evans J, Judy K, Glass J, Martinez N, Alnahhas I, Chervoneva I, Shi W. Concurrent Chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for Patients With Newly Diagnosed Glioblastoma May Increase the Rate of Distant Recurrence. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Ali A, Niazi M, Andrews D, Evans J, Judy K, Farrell C, Glass J, Kim L, Martinez N, Alnahhas I, Werner-Wasik M, Bar-Ad V, Leiby B, Shi W. Scalp-Sparing Volume Modulated Radiation Therapy (VMAT) for Newly Diagnosed Gliomas: A Phase 2 Trial. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Miller R, Song A, Ali A, Bar-Ad V, Martinez N, Glass J, Alnahhas I, Andrews D, Judy K, Evans J, Farrell C, Werner-Wasik M, Chervoneva I, Ly M, Palmer J, Liu H, Shi W. SPARE Trial: Scalp Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (200 kHz) for Patients With Newly Diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Bisinotto RS, Ribeiro ES, Greco LF, Taylor-Rodriguez D, Ealy AD, Ayres H, Lima FS, Martinez N, Thatcher WW, Santos JEP. Effects of progesterone concentrations and follicular wave during growth of the ovulatory follicle on conceptus and endometrial transcriptome in dairy cows. J Dairy Sci 2021; 105:889-903. [PMID: 34635351 DOI: 10.3168/jds.2021-20193] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Accepted: 06/21/2021] [Indexed: 11/19/2022]
Abstract
Objectives were to evaluate the effects of follicular wave and progesterone concentration on growth of the ovulatory follicle, conceptus elongation, uterine IFN-τ concentration, and transcriptome of conceptus and endometrium of pregnant cows on d 17 of gestation. Nonlactating nonpregnant Holstein cows were assigned randomly to one of 3 treatments: ovulation of a first-wave follicle (FW, n = 15); ovulation of a first-wave follicle and progesterone supplementation (FWP4, n = 12); and ovulation of a second-wave follicle (SW, n = 19). Ovulation of a first- or second-wave follicle was achieved by initiating the Ovsynch protocol (d -9 GnRH, d -2 and -1 PGF2α, d 0 GnRH and artificial insemination, d 0.7 artificial insemination) on d 0 or 6 of a presynchronized estrous cycle, respectively. Cows in FWP4 received 3 intravaginal inserts containing progesterone at 12, 24, and 48 h after the first GnRH injection that were removed on d -2. Cows were killed on d 17 for collection of the reproductive tract. Transcriptome was evaluated by microarray using the Affymetrix Bovine Array. Orthogonal contrasts were built to assess the effects of progesterone concentration during follicle growth (FW vs. FWP4 + SW) and follicular wave (FWP4 vs. SW). Progesterone concentrations (LSM ± SEM) from d -9 to -2 were greater for SW, followed by FWP4 and FW (5.38 ± 0.24, 4.26 ± 0.28, and 1.17 ± 0.27 ng/mL). Diameter of the ovulatory follicle (FW = 19.6 ± 0.6; FWP4 = 15.6 ± 0.6; SW = 15.2 ± 0.5 mm) and concentrations of estradiol from d -2 to 1 (FW = 4.05 ± 0.33; FWP4 = 2.73 ± 0.35; SW = 2.48 ± 0.30 pg/mL) were greater for FW compared with FWP4 and SW. Progesterone concentrations from d 3 to 16 were greater for FW compared with FWP4 and SW. A total of 28 singleton conceptuses were collected (FW, n = 8; FWP4, n = 8; SW, n = 12) and only intact conceptuses were included in the analyses of length (FW, n = 8; FWP4, n = 6; SW, n = 12). Although conceptuses were longer for FW compared with FWP4 and SW (FW = 16.6 ± 2.3; FWP4 = 9.8 ± 2.2; SW = 9.6 ± 2.0 cm), treatment did not affect the amount of IFN-τ in uterine flushing. Transcriptome of conceptuses and endometrium of pregnant cows was not extensively affected by follicular wave (8 and 1 differentially expressed transcripts) or concentration of progesterone during follicle growth (0 and 3 differentially expressed transcripts), showing that these factors did not affect conceptuses and endometrium transcriptome in pregnancies that are maintained to d 17.
Collapse
|
15
|
Yuan Y, Lee J, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Padam S, Tang A, Martinez N, Schmolze D, Presant C, Ebrahimi B, Yeon C, Sedrak M, Patel N, Portnow J, Lee P, Mortimer J. Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. Eur J Cancer 2021; 154:11-20. [PMID: 34217908 PMCID: PMC8691850 DOI: 10.1016/j.ejca.2021.05.035] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 05/11/2021] [Accepted: 05/24/2021] [Indexed: 01/15/2023]
Abstract
BACKGROUND CDK4/6 inhibitors modulate immune response in breast cancer. This phase I/II trial was designed to test the safety and efficacy of palbociclib, pembrolizumab and letrozole in women with hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC). PATIENTS AND METHODS Women with stage IV HR+ HER2- MBC were enrolled and treated with palbociclib, pembrolizumab and letrozole. Primary end-points were safety, tolerability and efficacy. RESULTS Between November 2016 and July 2020, 23 patients were enrolled with 20 evaluable for response, including 4 patients in cohort 1 and 16 patients in cohort 2. Cohort 1 median age was 48 years (33-70) and cohort 2 median age was 55 (37-75). Cohort 1 closed early due to limited accrual. Grade III-IV adverse events were neutropenia (83%), leucopaenia (65%), thrombocytopenia (17%) and elevated liver enzymes (17%). In cohort 1, 50% achieved a partial response (PR) and 50% had stable disease (SD). In cohort 2, 31% achieved complete response (CR), 25% had PR and 31% had SD by Response Evaluation Criteria in Solid Tumours version 1.1. Median progression-free survival was 25.2 months (95% confidence interval [CI] 5.3, not reached) and median overall survival was 36.9 months (95% CI 36.9, not reached) in cohort 2 with a median follow-up of 24.8 months (95% CI 17.1, not reached). A correlative immune biomarker analysis was published separately. CONCLUSION The combination of palbociclib, pembrolizumab and letrozole is well tolerated, and a complete response rate of 31% was identified in HR+ MBC patients who received this combination as front-line therapy. Confirmatory trials are required to better understand the immune-priming effects of CDK4/6 inhibitors.
Collapse
|
16
|
Abi B, Acciarri R, Acero MA, Adamov G, Adams D, Adinolfi M, Ahmad Z, Ahmed J, Alion T, Monsalve SA, Alt C, Anderson J, Andreopoulos C, Andrews MP, Andrianala F, Andringa S, Ankowski A, Antonova M, Antusch S, Aranda-Fernandez A, Ariga A, Arnold LO, Arroyave MA, Asaadi J, Aurisano A, Aushev V, Autiero D, Azfar F, Back H, Back JJ, Backhouse C, Baesso P, Bagby L, Bajou R, Balasubramanian S, Baldi P, Bambah B, Barao F, Barenboim G, Barker GJ, Barkhouse W, Barnes C, Barr G, Monarca JB, Barros N, Barrow JL, Bashyal A, Basque V, Bay F, Alba JLB, Beacom JF, Bechetoille E, Behera B, Bellantoni L, Bellettini G, Bellini V, Beltramello O, Belver D, Benekos N, Neves FB, Berger J, Berkman S, Bernardini P, Berner RM, Berns H, Bertolucci S, Betancourt M, Bezawada Y, Bhattacharjee M, Bhuyan B, Biagi S, Bian J, Biassoni M, Biery K, Bilki B, Bishai M, Bitadze A, Blake A, Siffert BB, Blaszczyk FDM, Blazey GC, Blucher E, Boissevain J, Bolognesi S, Bolton T, Bonesini M, Bongrand M, Bonini F, Booth A, Booth C, Bordoni S, Borkum A, Boschi T, Bostan N, Bour P, Boyd SB, Boyden D, Bracinik J, Braga D, Brailsford D, Brandt A, Bremer J, Brew C, Brianne E, Brice SJ, Brizzolari C, Bromberg C, Brooijmans G, Brooke J, Bross A, Brunetti G, Buchanan N, Budd H, Caiulo D, Calafiura P, Calcutt J, Calin M, Calvez S, Calvo E, Camilleri L, Caminata A, Campanelli M, Caratelli D, Carini G, Carlus B, Carniti P, Terrazas IC, Carranza H, Castillo A, Castromonte C, Cattadori C, Cavalier F, Cavanna F, Centro S, Cerati G, Cervelli A, Villanueva AC, Chalifour M, Chang C, Chardonnet E, Chatterjee A, Chattopadhyay S, Chaves J, Chen H, Chen M, Chen Y, Cherdack D, Chi C, Childress S, Chiriacescu A, Cho K, Choubey S, Christensen A, Christian D, Christodoulou G, Church E, Clarke P, Coan TE, Cocco AG, Coelho JAB, Conley E, Conrad JM, Convery M, Corwin L, Cotte P, Cremaldi L, Cremonesi L, Crespo-Anadón JI, Cristaldo E, Cross R, Cuesta C, Cui Y, Cussans D, Dabrowski M, da Motta H, Peres LDS, David C, David Q, Davies GS, Davini S, Dawson J, De K, De Almeida RM, Debbins P, De Bonis I, Decowski MP, de Gouvêa A, De Holanda PC, De Icaza Astiz IL, Deisting A, De Jong P, Delbart A, Delepine D, Delgado M, Dell’Acqua A, De Lurgio P, de Mello Neto JRT, DeMuth DM, Dennis S, Densham C, Deptuch G, De Roeck A, De Romeri V, De Vries JJ, Dharmapalan R, Dias M, Diaz F, Díaz JS, Di Domizio S, Di Giulio L, Ding P, Di Noto L, Distefano C, Diurba R, Diwan M, Djurcic Z, Dokania N, Dolinski MJ, Domine L, Douglas D, Drielsma F, Duchesneau D, Duffy K, Dunne P, Durkin T, Duyang H, Dvornikov O, Dwyer DA, Dyshkant AS, Eads M, Edmunds D, Eisch J, Emery S, Ereditato A, Escobar CO, Sanchez LE, Evans JJ, Ewart E, Ezeribe AC, Fahey K, Falcone A, Farnese C, Farzan Y, Felix J, Fernandez-Martinez E, Fernandez Menendez P, Ferraro F, Fields L, Filkins A, Filthaut F, Fitzpatrick RS, Flanagan W, Fleming B, Flight R, Fowler J, Fox W, Franc J, Francis K, Franco D, Freeman J, Freestone J, Fried J, Friedland A, Fuess S, Furic I, Furmanski AP, Gago A, Gallagher H, Gallego-Ros A, Gallice N, Galymov V, Gamberini E, Gamble T, Gandhi R, Gandrajula R, Gao S, Garcia-Gamez D, García-Peris MÁ, Gardiner S, Gastler D, Ge G, Gelli B, Gendotti A, Gent S, Ghorbani-Moghaddam Z, Gibin D, Gil-Botella I, Girerd C, Giri AK, Gnani D, Gogota O, Gold M, Gollapinni S, Gollwitzer K, Gomes RA, Bermeo LVG, Fajardo LSG, Gonnella F, Gonzalez-Cuevas JA, Goodman MC, Goodwin O, Goswami S, Gotti C, Goudzovski E, Grace C, Graham M, Gramellini E, Gran R, Granados E, Grant A, Grant C, Gratieri D, Green P, Green S, Greenler L, Greenwood M, Greer J, Griffith WC, Groh M, Grudzinski J, Grzelak K, Gu W, Guarino V, Guenette R, Guglielmi A, Guo B, Guthikonda KK, Gutierrez R, Guzowski P, Guzzo MM, Gwon S, Habig A, Hackenburg A, Hadavand H, Haenni R, Hahn A, Haigh J, Haiston J, Hamernik T, Hamilton P, Han J, Harder K, Harris DA, Hartnell J, Hasegawa T, Hatcher R, Hazen E, Heavey A, Heeger KM, Heise J, Hennessy K, Henry S, Morquecho MAH, Herner K, Hertel L, Hesam AS, Hewes J, Higuera A, Hill T, Hillier SJ, Himmel A, Hoff J, Hohl C, Holin A, Hoppe E, Horton-Smith GA, Hostert M, Hourlier A, Howard B, Howell R, Huang J, Huang J, Hugon J, Iles G, Ilic N, Iliescu AM, Illingworth R, Ioannisian A, Itay R, Izmaylov A, James E, Jargowsky B, Jediny F, Jesùs-Valls C, Ji X, Jiang L, Jiménez S, Jipa A, Joglekar A, Johnson C, Johnson R, Jones B, Jones S, Jung CK, Junk T, Jwa Y, Kabirnezhad M, Kaboth A, Kadenko I, Kamiya F, Karagiorgi G, Karcher A, Karolak M, Karyotakis Y, Kasai S, Kasetti SP, Kashur L, Kazaryan N, Kearns E, Keener P, Kelly KJ, Kemp E, Ketchum W, Kettell SH, Khabibullin M, Khotjantsev A, Khvedelidze A, Kim D, King B, Kirby B, Kirby M, Klein J, Koehler K, Koerner LW, Kohn S, Koller PP, Kordosky M, Kosc T, Kose U, Kostelecký VA, Kothekar K, Krennrich F, Kreslo I, Kudenko Y, Kudryavtsev VA, Kulagin S, Kumar J, Kumar R, Kuruppu C, Kus V, Kutter T, Lambert A, Lande K, Lane CE, Lang K, Langford T, Lasorak P, Last D, Lastoria C, Laundrie A, Lawrence A, Lazanu I, LaZur R, Le T, Learned J, LeBrun P, Miotto GL, Lehnert R, de Oliveira MAL, Leitner M, Leyton M, Li L, Li S, Li SW, Li T, Li Y, Liao H, Lin CS, Lin S, Lister A, Littlejohn BR, Liu J, Lockwitz S, Loew T, Lokajicek M, Lomidze I, Long K, Loo K, Lorca D, Lord T, LoSecco JM, Louis WC, Luk KB, Luo X, Lurkin N, Lux T, Luzio VP, MacFarland D, Machado AA, Machado P, Macias CT, Macier JR, Maddalena A, Madigan P, Magill S, Mahn K, Maio A, Maloney JA, Mandrioli G, Maneira J, Manenti L, Manly S, Mann A, Manolopoulos K, Plata MM, Marchionni A, Marciano W, Marfatia D, Mariani C, Maricic J, Marinho F, Marino AD, Marshak M, Marshall C, Marshall J, Marteau J, Martin-Albo J, Martinez N, Caicedo DAM, Martynenko S, Mason K, Mastbaum A, Masud M, Matsuno S, Matthews J, Mauger C, Mauri N, Mavrokoridis K, Mazza R, Mazzacane A, Mazzucato E, McCluskey E, McConkey N, McFarland KS, McGrew C, McNab A, Mefodiev A, Mehta P, Melas P, Mellinato M, Mena O, Menary S, Mendez H, Menegolli A, Meng G, Messier MD, Metcalf W, Mewes M, Meyer H, Miao T, Michna G, Miedema T, Migenda J, Milincic R, Miller W, Mills J, Milne C, Mineev O, Miranda OG, Miryala S, Mishra CS, Mishra SR, Mislivec A, Mladenov D, Mocioiu I, Moffat K, Moggi N, Mohanta R, Mohayai TA, Mokhov N, Molina J, Bueno LM, Montanari A, Montanari C, Montanari D, Zetina LMM, Moon J, Mooney M, Moor A, Moreno D, Morgan B, Morris C, Mossey C, Motuk E, Moura CA, Mousseau J, Mu W, Mualem L, Mueller J, Muether M, Mufson S, Muheim F, Muir A, Mulhearn M, Muramatsu H, Murphy S, Musser J, Nachtman J, Nagu S, Nalbandyan M, Nandakumar R, Naples D, Narita S, Navas-Nicolás D, Nayak N, Nebot-Guinot M, Necib L, Negishi K, Nelson JK, Nesbit J, Nessi M, Newbold D, Newcomer M, Newhart D, Nichol R, Niner E, Nishimura K, Norman A, Norrick A, Northrop R, Novella P, Nowak JA, Oberling M, Del Campo AO, Olivier A, Onel Y, Onishchuk Y, Ott J, Pagani L, Pakvasa S, Palamara O, Palestini S, Paley JM, Pallavicini M, Palomares C, Pantic E, Paolone V, Papadimitriou V, Papaleo R, Papanestis A, Paramesvaran S, Park JC, Parke S, Parsa Z, Parvu M, Pascoli S, Pasqualini L, Pasternak J, Pater J, Patrick C, Patrizii L, Patterson RB, Patton SJ, Patzak T, Paudel A, Paulos B, Paulucci L, Pavlovic Z, Pawloski G, Payne D, Pec V, Peeters SJM, Penichot Y, Pennacchio E, Penzo A, Peres OLG, Perry J, Pershey D, Pessina G, Petrillo G, Petta C, Petti R, Piastra F, Pickering L, Pietropaolo F, Pillow J, Pinzino J, Plunkett R, Poling R, Pons X, Poonthottathil N, Pordes S, Potekhin M, Potenza R, Potukuchi BVKS, Pozimski J, Pozzato M, Prakash S, Prakash T, Prince S, Prior G, Pugnere D, Qi K, Qian X, Raaf JL, Raboanary R, Radeka V, Rademacker J, Radics B, Rafique A, Raguzin E, Rai M, Rajaoalisoa M, Rakhno I, Rakotondramanana HT, Rakotondravohitra L, Ramachers YA, Rameika R, Delgado MAR, Ramson B, Rappoldi A, Raselli G, Ratoff P, Ravat S, Razafinime H, Real JS, Rebel B, Redondo D, Reggiani-Guzzo M, Rehak T, Reichenbacher J, Reitzner SD, Renshaw A, Rescia S, Resnati F, Reynolds A, Riccobene G, Rice LCJ, Rielage K, Rigaut Y, Rivera D, Rochester L, Roda M, Rodrigues P, Alonso MJR, Rondon JR, Roeth AJ, Rogers H, Rosauro-Alcaraz S, Rossella M, Rout J, Roy S, Rubbia A, Rubbia C, Russell B, Russell J, Ruterbories D, Saakyan R, Sacerdoti S, Safford T, Sahu N, Sala P, Samios N, Sanchez MC, Sanders DA, Sankey D, Santana S, Santos-Maldonado M, Saoulidou N, Sapienza P, Sarasty C, Sarcevic I, Savage G, Savinov V, Scaramelli A, Scarff A, Scarpelli A, Schaffer T, Schellman H, Schlabach P, Schmitz D, Scholberg K, Schukraft A, Segreto E, Sensenig J, Seong I, Sergi A, Sergiampietri F, Sgalaberna D, Shaevitz MH, Shafaq S, Shamma M, Sharma HR, Sharma R, Shaw T, Shepherd-Themistocleous C, Shin S, Shooltz D, Shrock R, Simard L, Simos N, Sinclair J, Sinev G, Singh J, Singh J, Singh V, Sipos R, Sippach FW, Sirri G, Sitraka A, Siyeon K, Smargianaki D, Smith A, Smith A, Smith E, Smith P, Smolik J, Smy M, Snopok P, Nunes MS, Sobel H, Soderberg M, Salinas CJS, Söldner-Rembold S, Solomey N, Solovov V, Sondheim WE, Sorel M, Soto-Oton J, Sousa A, Soustruznik K, Spagliardi F, Spanu M, Spitz J, Spooner NJC, Spurgeon K, Staley R, Stancari M, Stanco L, Steiner HM, Stewart J, Stillwell B, Stock J, Stocker F, Stocks D, Stokes T, Strait M, Strauss T, Striganov S, Stuart A, Summers D, Surdo A, Susic V, Suter L, Sutera CM, Svoboda R, Szczerbinska B, Szelc AM, Talaga R, Tanaka HA, Oregui BT, Tapper A, Tariq S, Tatar E, Tayloe R, Teklu AM, Tenti M, Terao K, Ternes CA, Terranova F, Testera G, Thea A, Thompson JL, Thorn C, Timm SC, Todd J, Tonazzo A, Torti M, Tortola M, Tortorici F, Totani D, Toups M, Touramanis C, Trevor J, Trzaska WH, Tsai YT, Tsamalaidze Z, Tsang KV, Tsverava N, Tufanli S, Tull C, Tyley E, Tzanov M, Uchida MA, Urheim J, Usher T, Vagins MR, Vahle P, Valdiviesso GA, Valencia E, Vallari Z, Valle JWF, Vallecorsa S, Berg RV, de Water RGV, Forero DV, Varanini F, Vargas D, Varner G, Vasel J, Vasseur G, Vaziri K, Ventura S, Verdugo A, Vergani S, Vermeulen MA, Verzocchi M, de Souza HV, Vignoli C, Vilela C, Viren B, Vrba T, Wachala T, Waldron AV, Wallbank M, Wang H, Wang J, Wang Y, Wang Y, Warburton K, Warner D, Wascko M, Waters D, Watson A, Weatherly P, Weber A, Weber M, Wei H, Weinstein A, Wenman D, Wetstein M, While MR, White A, Whitehead LH, Whittington D, Wilking MJ, Wilkinson C, Williams Z, Wilson F, Wilson RJ, Wolcott J, Wongjirad T, Wood K, Wood L, Worcester E, Worcester M, Wret C, Wu W, Wu W, Xiao Y, Yang G, Yang T, Yershov N, Yonehara K, Young T, Yu B, Yu J, Zaki R, Zalesak J, Zambelli L, Zamorano B, Zani A, Zazueta L, Zeller GP, Zennamo J, Zeug K, Zhang C, Zhao M, Zhao Y, Zhivun E, Zhu G, Zimmerman ED, Zito M, Zucchelli S, Zuklin J, Zutshi V, Zwaska R. Prospects for beyond the Standard Model physics searches at the Deep Underground Neutrino Experiment: DUNE Collaboration. THE EUROPEAN PHYSICAL JOURNAL. C, PARTICLES AND FIELDS 2021; 81:322. [PMID: 34720713 PMCID: PMC8550327 DOI: 10.1140/epjc/s10052-021-09007-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 02/23/2021] [Indexed: 06/13/2023]
Abstract
The Deep Underground Neutrino Experiment (DUNE) will be a powerful tool for a variety of physics topics. The high-intensity proton beams provide a large neutrino flux, sampled by a near detector system consisting of a combination of capable precision detectors, and by the massive far detector system located deep underground. This configuration sets up DUNE as a machine for discovery, as it enables opportunities not only to perform precision neutrino measurements that may uncover deviations from the present three-flavor mixing paradigm, but also to discover new particles and unveil new interactions and symmetries beyond those predicted in the Standard Model (SM). Of the many potential beyond the Standard Model (BSM) topics DUNE will probe, this paper presents a selection of studies quantifying DUNE's sensitivities to sterile neutrino mixing, heavy neutral leptons, non-standard interactions, CPT symmetry violation, Lorentz invariance violation, neutrino trident production, dark matter from both beam induced and cosmogenic sources, baryon number violation, and other new physics topics that complement those at high-energy colliders and significantly extend the present reach.
Collapse
Grants
- MR/T019530/1 Medical Research Council
- MR/T041323/1 Medical Research Council
- MSMT, Czech Republic
- NRF, South Korea
- Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- SERI, Switzerland
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- U.S. Department of Energy
- CERN
- Türkiye Bilimsel ve Teknolojik Arastirma Kurumu
- The Royal Society, United Kingdom
- Canada Foundation for Innovation
- U.S. NSF
- FCT, Portugal
- CEA, France
- CNRS/IN2P3, France
- European Regional Development Fund
- Science and Technology Facilities Council
- H2020-EU, European Union
- IPP, Canada
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- CAM, Spain
- MSCA, European Union
- Instituto Nazionale di Fisica Nucleare
- Fundacção de Amparo à Pesquisa do Estado de Goiás
- Ministerio de Ciencia e Innovación
- Fundacion “La Caixa” Spain
Collapse
|
17
|
Morgado-Carrasco D, Feola H, Fustà-Novell X, Martinez N. RF-Nevi With Moderate Dysplasia Excised With Positive Surgical Margins: Should We Re-Excise? ACTAS DERMO-SIFILIOGRAFICAS 2020. [DOI: 10.1016/j.adengl.2019.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
18
|
Yélamos O, Alejo B, Ertekin SS, Villa-Crespo L, Zamora-Barquero S, Martinez N, Domínguez M, Iglesias P, Herrero A, Malvehy J, Puig S. Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial. J Eur Acad Dermatol Venereol 2020; 35:143-149. [PMID: 32365242 PMCID: PMC7818495 DOI: 10.1111/jdv.16559] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2020] [Accepted: 04/10/2020] [Indexed: 01/07/2023]
Abstract
BACKGROUND Treatment response for psoriasis is typically evaluated using clinical scores. However, patients can relapse after clinical clearance, suggesting persistent inflammation. Dermoscopy, reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) can non-invasively improve treatment response assessment. OBJECTIVES To compare the clinical and non-invasive microscopic features in a psoriatic target lesion treated with clobetasol cream or calcipotriol/betamethasone dipropionate foam (Cal/BD foam). METHODS Prospective, unicentric, open, randomized clinical trial comparing clinical data [total clinical score (TCS)] and microscopic data (dermoscopy, RCM and OCT) in psoriasis patients treated with clobetasol or Cal/BD foam. RESULTS We included 36 adult patients (22 men). At week 4, more patients treated with Cal/BD foam achieved TCS ≤1 than with clobetasol (63.2% vs. 18.8%, P = 0.016). Treatment satisfaction was higher with Cal/BD foam (P < 0.03). Microscopically, Cal/BD foam induced more reduction in epidermal thickness at week 4 (P < 0.049). Dilated horizontal blood vessels were more common with clobetasol than with Cal/BD foam at week 8 (69.2% vs. 31.2%, P = 0.159). If epidermal hyperplasia was noted at baseline, the response was poorer with clobetasol (P = 0.029). LIMITATIONS Small sample size, open study, imaging sampling bias. CONCLUSION Cal/BD foam is more effective than clobetasol, has better patient satisfaction and induces greater reduction in the hyperkeratosis/acanthosis, regardless of baseline epidermal hyperplasia.
Collapse
|
19
|
Martinez N, Kornfeld H. Tuberculosis and diabetes: from bench to bedside and back. Int J Tuberc Lung Dis 2020; 23:669-677. [PMID: 31315698 DOI: 10.5588/ijtld.18.0805] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
People living with diabetes (DM) are at increased risk to become infected with Mycobacterium tuberculosis, to progress from latent tuberculous infection to active tuberculosis (TB) disease, and to suffer adverse TB treatment outcomes. In some low- and middle-income countries, DM prevalence among newly diagnosed TB patients exceeds 40%. Despite the global significance of DM as an acquired TB risk factor, the biochemical and cellular mechanisms of susceptibility are incompletely understood. This review summarizes the landscape of basic research using animal models of the TB-DM interaction, and the extent to which findings in animal studies reflect or may explain the clinical features of TB-DM comorbidity in humans. We conclude that immunopathy results in damage to major organs as a complication of DM, likely operating through biochemical pathways such as those responsible for diabetic nephropathy, neuropathy, retinopathy, cardiovascular disease, and delayed wound healing. Insights gained from animal models can inform optimal management of TB-DM comorbidity and will be essential for pre-clinical development of therapeutic countermeasures.
Collapse
|
20
|
Pérez-Báez J, Risco CA, Chebel RC, Gomes GC, Greco LF, Tao S, Thompson IM, do Amaral BC, Zenobi MG, Martinez N, Staples CR, Dahl GE, Hernández JA, Santos JEP, Galvão KN. Association of dry matter intake and energy balance prepartum and postpartum with health disorders postpartum: Part II. Ketosis and clinical mastitis. J Dairy Sci 2019; 102:9151-9164. [PMID: 31326169 DOI: 10.3168/jds.2018-15879] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 05/26/2019] [Indexed: 01/19/2023]
Abstract
The main objective of this study was to determine the association of dry matter intake as percentage of body weight (DMI%BW) and energy balance (EB) prepartum (-21 d relative to parturition) and postpartum (28 d) with ketosis (n = 189) and clinical mastitis (n = 79). For this, DMI%BW and EB were the independent variables and ketosis and clinical mastitis were the dependent variables. A secondary objective was to evaluate prepartum DMI%BW and EB as predictors of ketosis and clinical mastitis. For this, ketosis and clinical mastitis were the independent variables and DMI%BW and EB were the dependent variables. Data from 476 cows from 9 experiments were compiled. Clinical mastitis was diagnosed if milk from 1 or more quarters was abnormal in color, viscosity, or consistency, with or without accompanying heat, pain, redness, or swelling of the quarter or generalized illness, during the first 28 d postpartum. Ketosis was defined as the presence of acetoacetate in urine that resulted in any color change [5 mg/dL (trace) or higher] in the urine test strip (Ketostix, Bayer, Leverkusen, Germany). Cows that developed ketosis had lesser DMI%BW and lesser EB on d -5, -3, -2, and -1 than cows without ketosis. Each 0.1-percentage point decrease in the average DMI%BW and each 1-Mcal decrease in the average of EB in the last 3 d prepartum increased the odds of having ketosis by 8 and 5%, respectively. Cut-offs for DMI%BW and EB during the last 3 d prepartum to predict ketosis were established and were ≤1.5%/d and ≤1.1 Mcal/d, respectively. Cows that developed ketosis had lesser postpartum DMI%BW and EB and greater energy-corrected milk (ECM) than cows without ketosis. Cows that developed clinical mastitis had lesser DMI%BW but similar prepartum EB compared with cows without clinical mastitis. Each 0.1-percentage point decrease in the average DMI%BW and each 1-Mcal decrease in the average EB in the last 3 d prepartum increased the odds of having clinical mastitis by 10 and 8%, respectively. The average DMI%BW and EB during the last 3 d prepartum produced significant cut-offs to predict clinical mastitis postpartum, which were ≤1.2%/d and ≤1.0 Mcal/d, respectively. Cows that developed clinical mastitis had lesser postpartum DMI%BW from d 3 to 15 and on d 17; greater EB on d 18, from d 21 to 23, and on d 26; and lesser ECM. The main limitation in this study is that the time-order of disease relative to DMI%BW and ECM is inconsistent such that postpartum outcomes were measured before and after disease, which was diagnosed at variable intervals after calving. In summary, measures of prepartum DMI were associated with and were predictors of ketosis and clinical mastitis postpartum, although the effect sizes were small.
Collapse
|
21
|
Pérez-Báez J, Risco CA, Chebel RC, Gomes GC, Greco LF, Tao S, Thompson IM, do Amaral BC, Zenobi MG, Martinez N, Staples CR, Dahl GE, Hernández JA, Santos JEP, Galvão KN. Association of dry matter intake and energy balance prepartum and postpartum with health disorders postpartum: Part I. Calving disorders and metritis. J Dairy Sci 2019; 102:9138-9150. [PMID: 31326177 DOI: 10.3168/jds.2018-15878] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 05/26/2019] [Indexed: 12/17/2022]
Abstract
The main objective of this study was to determine the association of dry matter intake as percentage of body weight (DMI%BW) and energy balance (EB) prepartum (-21 d relative to parturition) and postpartum (28 d) with calving disorders (CDZ; dystocia, twins, and stillbirths; n = 101) and metritis (n = 114). For this, DMI%BW and EB were the independent variables and CDZ and metritis were the dependent variables. A secondary objective was to evaluate prepartum DMI%BW and EB as predictors of CDZ and metritis. For this, CDZ and metritis were the independent variables and DMI%BW and EB were the dependent variables. Data from 476 cows from 9 experiments were compiled. Cows that developed CDZ had lesser postpartum DMI%BW from d 3 to 12 and lesser energy-corrected milk (ECM) than cows that did not develop CDZ. Dry matter intake as percentage of BW and EB prepartum did not affect the odds of CDZ. Cows with metritis had lesser prepartum DMI%BW and EB. Each 0.1-percentage point decrease in the average DMI%BW and each 1-Mcal decrease in the average EB in the last 3 d prepartum increased the odds of having metritis by 8%. The average DMI%BW and EB during the last 3 d prepartum produced significant cut-offs to predict metritis postpartum, which were ≤1.6%/d and ≤2.5 Mcal/d, respectively. Cows that developed metritis had lesser overall postpartum DMI%BW and ECM and lesser EB from d 2 to 5 and from d 7 to 11 than cows that did not develop metritis. The main limitation in this study is that the time-order of disease relative to DMI%BW and ECM is inconsistent such that postpartum outcomes were measured before and after disease, which was diagnosed at variable intervals after calving. In summary, prepartum DMI%BW and EB were associated with and were predictors of metritis although the effect sizes were small for metritis, and calving disorders and metritis were associated with decreased DMI%BW and ECM postpartum.
Collapse
|
22
|
Llombart A, Andrés R, Anton Torres A, Martinez N, Rodriguez C, Sánchez-Rovira P, Rojas B, Ruiz Borrego M, Bermejo B, Martinez de Dueñas E. Impact of the 21-gene assay on treatment decisions in high-risk patients with ER-positive HER2-negative early breast cancer: Results of the KARMA Dx study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz095.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
23
|
Martin Huertas R, Lopez Miranda E, Corral de la Fuente E, Serrano Domingo J, Fernandez Abad M, Martinez N, Guerra E, Cortes Salgado A, Gion Cortes M, Carrato Mena A. Efficacy of trastuzumab-emtansina (T-DM1) in HER2-positive breast cancer (BC) with brain metastases (BM): A single institution experience. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz100.039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Delaloge S, Cella D, Ye Y, Buyse M, Chan A, Barrios CH, Holmes FA, Mansi J, Iwata H, Ejlertsen B, Moy B, Chia SKL, Gnant M, Smichkoska S, Ciceniene A, Martinez N, Filipović S, Ben-Baruch NE, Joy AA, Langkjer ST, Senecal F, de Boer RH, Moran S, Yao B, Bryce R, Auerbach A, Fallowfield L, Martin M. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Ann Oncol 2019; 30:567-574. [PMID: 30689703 DOI: 10.1093/annonc/mdz016] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adjuvant therapy with neratinib over placebo in human epidermal growth factor receptor-2-positive early-stage breast cancer. PATIENTS AND METHODS Women (N = 2840) with early-stage HER2-positive breast cancer who had completed trastuzumab-based adjuvant therapy were randomly assigned to neratinib 240 mg/day or placebo for 12 months. HRQoL was an exploratory end point. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQol 5-Dimensions (EQ-5D) questionnaires at baseline and months 1, 3, 6, 9, and 12. Changes from baseline were compared using analysis of covariance with no imputation for missing values. Sensitivity analyses used alternative methods. Changes in HRQoL scores were regarded as clinically meaningful if they exceeded previously reported important differences (IDs). RESULTS Of the 2840 patients (intention-to-treat population), 2407 patients were evaluable for FACT-B (neratinib, N = 1171; placebo, N = 1236) and 2427 patients for EQ-5D (neratinib, N = 1186; placebo, N = 1241). Questionnaire completion rates exceeded 85%. Neratinib was associated with a decrease in global HRQoL scores at month 1 compared with placebo (adjusted mean differences: FACT-B total, -2.9 points; EQ-5D index, -0.02), after which between-group differences diminished at later time-points. Except for the FACT-B physical well-being (PWB) subscale at month 1; all between-group differences were less than reported IDs. The FACT-B breast cancer-specific subscale showed small improvements with neratinib at months 3-9, but all were less than IDs. Sensitivity analyses exploring missing data did not change the results. CONCLUSIONS Extended adjuvant neratinib was associated with a transient, reversible decrease in HRQoL during the first month of treatment, possibly linked to treatment-related diarrhea. With the exception of the PWB subscale at month 1, all neratinib-related HRQoL changes did not reach clinically meaningful thresholds. ClinicalTrials.gov: NCT00878709.
Collapse
|
25
|
Brasó-Maristany F, Griguolo G, Llombart-Cussac A, Pascual T, Paré L, Bermejo B, Oliveira M, Morales S, Martinez N, Vidal M, Pernas S, Lopez R, Muñoz M, Galvan P, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Cortés J, Prat A. Abstract P6-17-07: Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2-positive (HER2+) breast cancer (BC) is composed of 4 molecular subtypes: Luminal A and B, HER2-enriched (HER2-E) and Basal-like. Among them, the HER2-E is highly sensitive to anti-HER2 treatment. However, ˜60% of HER2-E tumors do not achieve a pathological complete response (pCR) following neoadjuvant dual HER2 blockade without chemotherapy. Here, we aimed to better understand the molecular changes of the HER2-E subtype during anti-HER2 treatment.
Methods: Gene expression was evaluated in 101 patients with HER2-E tumors from the PAMELA neoadjuvant phase II trial (Lancet Oncol 2017). Briefly, women with HER2+ BC were treated with lapatinib and trastuzumab (and hormonal therapy if hormone receptor [HR]-positive) for 18 weeks. The median time between the last dose of treatment and surgery was 35 days (range=213; interquartile range=16). Expression of the PAM50 genes and 6 PAM50 signatures (Luminal A, Luminal B, HER2-E, Basal-like, normal-like and the PAM50 proliferation score) were determined using the nCounter platform at baseline (n=101), after 2 weeks of treatment (n=96) and in residual tumors (non-pCR) at surgery (n=57). Same analyses were done in 2 HER2+/HER2-E cell line models (BT474 [HR+] and SKBR3 [HR-]) following in vitro treatment with trastuzumab in combination with lapatinib. Biological changes between 2 time-points were determined by paired t-tests with a false discovery rate (FDR) <5%.
Results: After 2 weeks of treatment, 85.7% and 94.6% of the 56 genes/signatures were found differentially expressed (FDR<5%) in HER2-E/HR+ (n=35) and HER2-E/HR- (n=61) tumors, respectively. The two gene lists were highly correlated (correlation coefficient=0.93). Overall, a significant relative increase in Luminal A and normal-like signature scores, and a relative decrease in proliferation, HER2-E and Luminal B signature scores, were observed between baseline and week 2. Interestingly, a PAM50 subtype switch to Luminal A was observed in 31.6% and 4.8% of HER2-E/HR+ and HER2-E/HR- tumors. In BT474 and SKBR3, all genes/signatures were also found differentially expressed (FDR<5%) following 72h of dual HER2 blockade. The in vitro findings recapitulated the in vivo findings in 80-86% of the genes/signatures. Similar to tumors, a switch to a Luminal A subtype following dual HER2 blockade was observed in BT474 but not in SKBR3. Finally, 92.9% of the 56 genes/signatures were found differentially expressed (FDR<5%) in residual tumors at surgery compared to week 2. Contrary to the findings in the first 2 weeks of treatment, a general rebound effect in gene expression was observed between week 2 and surgery. Similarly, a rebound effect was observed in 60% of the genes/signatures in BT474 after removing anti-HER2 therapy for 72h, leading to a subtype switch from Luminal A back to HER2-E.
Conclusions: Dual HER2 blockade in the HER2-E subtype induces large biological changes that lead to a more low-proliferative Luminal A phenotype both in tumors and in vitro models, especially in HER2-E/HR+ disease. These phenotypic changes are reversible upon stopping anti-HER2 treatment. This finding supports the use of maintenance anti-HER2 treatment +/- endocrine therapy (if HR+) in advanced HER2+ BC.
Citation Format: Brasó-Maristany F, Griguolo G, Llombart-Cussac A, Pascual T, Paré L, Bermejo B, Oliveira M, Morales S, Martinez N, Vidal M, Pernas S, Lopez R, Muñoz M, Galvan P, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Cortés J, Prat A. Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-07.
Collapse
|